Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
RESEARCH TOOLSreports
Holding MRSN?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.15Last Year’s EPS
-$0.16Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -20.91%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strong financial management, and successful collaborations, indicating a positive outlook. However, challenges remain in addressing resistance to TOPO1 ADCs and uncertainties in benchmarking efficacy.Company Guidance
In the third quarter of 2024, Mersana Therapeutics reported significant advancements in their clinical trials and collaborations. They are actively dose escalating in their Phase I clinical trials for XMT-1660 and XMT-2056, with XMT-1660 reaching doses as high as 115 mg/m², significantly higher than previous levels. The company plans to disclose initial clinical data for XMT-1660 by the end of the year, focusing on safety, tolerability, and efficacy. Mersana ended the quarter with $155.2 million in cash, expecting to sustain operations into 2026. They reported a net loss of $11.5 million, a reduction from $41.7 million the previous year, attributed to portfolio reprioritization and strategic collaborations. Additionally, the company achieved milestones with partners Johnson & Johnson and Merck KGaA, underscoring their strategic focus on business development.Progress in Phase I Trials
Significant progress in Phase I clinical trials of XMT-1660 and XMT-2056, with dose escalation continuing and multiple milestones achieved in research collaborations.
Strong Financial Position
Ended Q3 with $155.2 million in cash, supporting operations into 2026. Net cash used in Q3 was significantly lower at $8.6 million compared to $46.1 million in the previous year.
Collaborations and Achievements
Milestones achieved under collaborations with Johnson & Johnson and Merck KGaA, contributing to increased collaboration revenue year-over-year.
Reduced Expenses
R&D expenses declined to $14.8 million from $30.5 million in 2023, and G&A expenses decreased to $9.9 million from $12.9 million, reflecting restructuring efforts.
---
MRSN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRSN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $2.20 | $2.63 | +19.55% |
| Aug 13, 2024 | $1.42 | $1.35 | -4.93% |
| May 09, 2024 | $3.40 | $2.46 | -27.65% |
| Feb 28, 2024 | $4.27 | $4.85 | +13.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mersana Therapeutics Inc (MRSN) report earnings?
Mersana Therapeutics Inc (MRSN) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Mersana Therapeutics Inc (MRSN) earnings time?
Mersana Therapeutics Inc (MRSN) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRSN EPS forecast?
MRSN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.15.
---